Please confirm you are human (Sign Up for free to never see this)
← Back to Search
The Prevention Of Anthracycline Cardiomyopathy
L. Steinherz, L. Wexler
Published 1998 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Abstract The use of anthracyclines, a family of chemotherapeutic agents with efficacy against many solid tumors and leukemias has been limited by their cardiotoxicity. This cardiotoxicity manifests as a reversible acute myopericarditis, an irreversible subacute cardiomyopathy and a progressive late, chronic form. It is particularly important in children who can be expected to survive decades after cure of their malignancy. The incidence of the subacute and late forms have been shown to increase with increasing peak and total cumulative anthracycline dose. Prevention of cardiotoxicity has been attempted by: (1) arbitrary limitation of total cumulative dose; (2) dose limitation guided by monitoring; (3) variation of administrative methods to decrease peak dose by the use of weekly divided boluses or continuous infusion; (4) liposomal encapsulation; (5) use of anthracycline analogues; and (6) concomitant administration of cardioprotective agents. The most promising cardioprotective agent, to date is an intracellular iron chelator which interferes with the formation of free radicals by the anthracyclines, thus limiting cardiac damage from lipid peroxidation. None of these methods has provided full cardiac protection, hence further study of the pathophysiology of anthracycline cardiotoxicity and its prevention is warranted as is long term monitoring of the cancer survivors who have received anthracyclines.
This paper references
Aclarubicin: Preclinical and clinical data suggesting less chronic cardiotoxicity compared with conventional anthracyclines
S. Mortensen (1987)
Cardiac toxicity after treatment for childhood cancer
J. Bricker (1993)
Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer.
G. Fountzilas (1992)
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
J. Mckillop (1983)
Effect of alpha-tocopherol on the cardiotoxicity of adriamycin in the rat.
P. Sonneveld (1978)
Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer.
C. Schwartz (1993)
Myocardial Uptake of 111In Monoclonal Antimyosin Fab in Detecting Doxorubicin Cardiotoxicity in Rats: Morphological and Hemodynamic Findings
M. Hiroe (1992)
G. Weiss (1999)
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors
L. Wexler (1996)
Antimyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity?
D. Jain (1990)
Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
C. T. Tan (1987)
Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study.
J. Milei (1987)
A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high‐grade extremity soft tissue sarcoma and an analysis of prognostic factors
E. Casper (1991)
Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.
S. Palmeri (1986)
Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy.
E. Herman (1990)
Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin.
F. Villani (1990)
Med Pediatr Oncol
W. A. Abdullah (1999)
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.
D. V. Von Hoff (1977)
Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
P. Alderton (1992)
Detection of Early Anthracycline Cardiotoxicity by Monitoring the Peak Filling Rate
W. Ganz (1993)
Early anthracycline cardiotoxicity.
M. Bristow (1978)
Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.
B. Neri (1989)
Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.
F. Bu'lock (1993)
Echocardiography in adriamycin cardiotoxicity
K. R. Bloom (1978)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
P. Alderton (1990)
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
S. Swain (1997)
Early identification of anthracycline cardiomyopathy: possibilities and implications.
F. Bu'lock (1996)
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.
M. Estorch (1993)
Assessment of left ventricular contractility in patients receiving doxorubicin.
K. Borow (1983)
Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.
D. Iarussi (1994)
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
L. Wexler (1996)
Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
A. Carella (1990)
Alterations in left ventricular diastolic function with doxorubicin therapy.
B. H. Lee (1987)
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.
F. Torti (1983)
Long-Term Cardiac Follow-up 4–13 Years after Anthracycline Therapy
L. Steinherz (1986)
Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture.
C. Hershko (1993)
Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect.
N. Siveski-Iliskovic (1995)
Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
N. G. Shipp (1993)
Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.
J. Kraft (1990)
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
J. Speyer (1992)
Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity
A. Weiss (1977)
Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
I. Carrio (1993)
Phase I trial of rubidazone (NSC 164011) in children with cancer.
C. Tan (1981)
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
J. Speyer (1988)
Early Prediction of Anthracycline Cardiomyopathy Using Standard M‐Mode and Digitized Echocardiography
G. Sandor (1992)
Effect of ketotifen on adriamycin toxicity: role of histamine.
F. Bartoli Klugman (1988)
Ventricular late potentials: another expression of cardiotoxicity of cytostatic drugs in children?
R. Tamminga (1992)
QRS voltage change with adriamycin administration.
R. A. Minow (1978)
Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy.
S. Wakasugi (1993)
Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography.
J. Gottdiener (1981)
Ascorbic acid and adriamycin toxicity.
K. Shimpo (1991)
Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy.
S. Bielack (1989)
Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
K. Sørensen (1997)
Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.
M. Estorch (1990)
Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
E. Herman (1981)
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
S. Swain (1997)
Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
E. Herman (1981)
Doxorubicin cardiotoxicity in children.
T. Biancaniello (1980)
Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity.
G. Perletti (1989)
I‐123 MIBG and Serial Radionuclide Angiocardiography in Doxorubicin‐related Cardiotoxicity
R. V. Valdés Olmos (1992)
Advances in anthracycline chemotherapy : epirubicin
G. Bonadonna (1984)
Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan‐Kettering‐New York‐II protocol
Peter G. Stenherz (1993)
Comparison of cardiac function tests after anthracycline therapy in childhood implications for screening
R. Jakacki (1993)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.
L. Steinherz (1995)
Exacerbation of doxorubicin cardiotoxicity by digoxin administration in an experimental rabbit model
W. Reeves (1990)
An in vivo animal model to study chronic adriamycin cardiotoxicity: a P-31 nuclear magnetic resonance spectroscopy investigation.
R. Thompson (1991)
ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.
M. Green (1991)
A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.
J. Speyer (1990)
Cardiac toxicity of adriamycin-DNA complex and rubidazone: evaluation by electrocardiogram and endomyocardial biopsy.
R. Benjamin (1978)
Noninvasive identification of anthracycline cardiotoxicity: Comparison of123I-MIBG and123I-BMIPP imaging
Y. Takeishi (1994)
Biochemical effects and toxicity of mitoxantrone in cultured heart cells.
N. G. Shipp (1991)
Effect of amrinone on anthracycline-induced lethal and cardiac toxicity in mice and rats
F. Villani (1990)
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
Increasing therapeutic effect and reducing toxicity of doxorubicin by N-acyl dehydroalanines.
P. Buc-Calderon (1989)
Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.
L. Steinherz (1992)
Reduced cardiotoxicity of doxorubicin by a 6‐hour infusion regimen. A prospective randomized evaluation
J. Shapira (1990)
Amelioration of 4'-epidoxorubicin-induced cardiotoxicity by sodium cromoglycate.
F. Klugmann (1989)
Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.
D. Nielsen (1990)
A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.
A. Rahman (1990)
Atrial natriuretic peptide as a marker for doxorubicin‐induced cardiotoxic effects
Martina Bauch (1992)
Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.
G. S. Harman (1988)
The Role of Prenylamine in the Prevention of Adriamycin-Induced Cardiotoxicity. A Review of Experimental and Clinical Findings
J. Milei (1988)
Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes.
H. Akimoto (1993)
High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography.
S. F. Gardner (1993)
This paper is referenced by
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
O. Hequet (2004)
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients
L. Elbl (2005)
Imaging of early modification in cardiomyopathy: the doxorubicin-induced model
M. Aissiou (2013)
Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS)
W. Stöhr (2005)
Late complications of childhood acute lymphoblastic leukaemia (ALL), with special reference to hormone secretion, cardiovascular risk and bone health
C. Follin (2010)
Cardiovascular Effects of Cancer Therapy
D. Briston (2015)
Late effects surveillance system for sarcoma patients
T. Langer (2004)
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up
L. Elbl (2005)